The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) hit a new 52-week low and has $317.41 target or 8.00% below today’s $345.01 share price. The 6 months bearish chart indicates high risk for the $36.18B company. The 1-year low was reported on Nov, 4 by Barchart.com. If the $317.41 price target is reached, the company will be worth $2.89 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 924,349 shares traded hands or 35.73% up from the average. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 17.10% since April 4, 2016 and is downtrending. It has underperformed by 18.19% the S&P500.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage
Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Neutral” rating by Robert W. Baird on Friday, August 5. As per Monday, August 31, the company rating was maintained by RBC Capital Markets. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Outperform” rating given on Wednesday, August 5 by RBC Capital Markets. The firm has “Sell” rating given on Wednesday, August 5 by UBS. The firm has “Outperform” rating by Leerink Swann given on Friday, February 5. The company was downgraded on Wednesday, January 27 by Canaccord Genuity. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. The firm has “Outperform” rating by Raymond James given on Tuesday, September 1. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Outperform” rating given on Wednesday, June 29 by Bernstein. The firm earned “Outperform” rating on Thursday, November 5 by RBC Capital Markets.
According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.44, from 0.75 in 2016Q1. The ratio increased, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Moreover, Blackrock Incorporated has 0.1% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 186,678 shares. Alexandria Cap Limited Company accumulated 0.3% or 4,866 shares. Stevens Mgmt Lp last reported 7,364 shares in the company. Manufacturers Life Company The accumulated 0.04% or 75,443 shares. Moreover, Martingale Asset Lp has 0.03% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 4,875 shares. Assetmark, a California-based fund reported 35 shares. Hl Fincl Svcs Limited Liability last reported 738 shares in the company. Parametric Risk Advsr Limited Liability Co accumulated 4,600 shares or 0.11% of the stock. Prudential holds 0.07% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 122,031 shares. The New York-based Alliancebernstein L P has invested 0.07% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Creative Planning holds 14,734 shares or 0.04% of its portfolio. Putnam Investments Limited Liability Corp owns 1,799 shares or 0% of their US portfolio. Alphamark Advsrs Lc has invested 0.01% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Fukoku Mutual Life Insurance owns 400 shares or 0.03% of their US portfolio. Advisors Asset Mgmt has 0.05% invested in the company for 8,900 shares.
Insider Transactions: Since May 17, 2016, the stock had 1 insider purchase, and 3 selling transactions for $20.55 million net activity. The insider Sanofi bought 64,731 shares worth $23.55M. $1.70 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was sold by Van Plew Daniel P on Tuesday, May 17. 1,000 shares were sold by RYAN ARTHUR F, worth $396,640 on Tuesday, May 24. The insider GOLDSTEIN JOSEPH L sold 2,125 shares worth $903,125.
More important recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Investorplace.com which released: “Regeneron Pharmaceuticals Inc (REGN) Stock Pops on Mixed Q3 Results” on November 04, 2016, also Fool.com published article titled: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG”, Fool.com published: “Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?” on October 10, 2016. More interesting news about Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was released by: Prnewswire.com and their article: “Science Magazine Once Again Names Regeneron the Best Company to Work For” with publication date: October 27, 2016.
REGN Company Profile
Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.